Bradley J. Lampe, MPH
NSF International
789 N. Dixboro Road
Ann Arbor, MI 48105

Re: GRAS Notice No. GRN 000687

Dear Mr. Lampe:

The Food and Drug Administration (FDA, we) is granting your request to cease our evaluation of GRN 000687, which we filed on February 8, 2017. We received your email request on April 20, 2017.

The subject of the notice is inulin from Agave tequilana. The notice informs FDA of Industrializadora Integral del Agave SA de CV (IIDEA)’s view that inulin from Agave tequilana is GRAS, through scientific procedures, for use as a general bulking agent, texturizing agent, or source of reduced energy carbohydrates for uses as a sugar replacer, fat-replacer and/or texture modifier in variety of foods (excluding meat and poultry products, and infant formulas) and beverage products at levels ranging from 1 to 15 g per 100 g or per serving.

In the April 20, 2017 email, you informed FDA that IIDEA was not able to provide analytical results and address administrative items requested in our letter dated March 14, 2007 by the agreed-upon deadline.

In accordance with 21 CFR 170.275(b)(3), the text of this letter responding to GRN 000687 is accessible to the public at www.fda.gov/grasnoticeinventory.

Sincerely,

Susan J. Carlson, Ph.D.
Director
Division of Biotechnology
and GRAS Notice Review
Office of Food Additive Safety
Center for Food Safety
and Applied Nutrition

U.S. Food & Drug Administration
Center for Food Safety & Applied Nutrition
5001 Campus Drive
College Park, MD 20740